Cell & Gene

A conversation between CuraCell CEO Torbjörn Ström and Clinical Leader Executive Editor Abby Proch T-cell therapies can be highly effective, but they’re not without their drawbacks. They can cause adverse health events, create manufacturing complexities, have limited effectiveness in solid tumors, and come at a high cost, thus inhibiting patient access.

A conversation with Peter Sagmeister and Aniket Udepurkar, MIT, and Life Science Connect's Jon O'Connell Lipid nanoparticles (LNPs) are becoming one of the most important enabling technologies behind nucleic acid therapeutics, but manufacturing them with consistent size, morphology, and quality remains a complex process development challenge.

This content is brought to you by Phenomenex, a Danaher Operating Company. Monoclonal antibodies have transformed biotherapeutic development, but their size and structural complexity make quality control especially demanding. One of the most important attributes to monitor is aggregation, which can occur at multiple points during manufacturing, storage, or formulation.

By Sonja Steinsiek, Sarah Wirth, and Igor Vassilev In bioprocess development, timely and consistent sampling is essential for understanding culture performance and maintaining product quality. Automated sampling technologies can reduce manual intervention while improving data reliability across long or complex runs.

Elevate your expertise, embrace innovation, and connect with the global leaders transforming bioprocessing for the digital age. The Bioprocessing Summit unites a global community of scientists, engineers, and executives driving innovation and digitalization across process development, scale-up, quality, and analytics for biologics, antibodies, cell and gene, RNA, and oligonucleotide therapies.

By Erin Harris, Editor-In-Chief, Cell & Gene Follow Me On Twitter @ErinHarris_1 The CGT industry has spent more than a decade proving that engineered cell therapies can transform outcomes in hematologic cancers. Solid tumors, however, have remained one of the field’s most difficult frontiers because of complex tumor biology, limited target availability, and challenges surrounding persistence, trafficking, and the tumor microenvironment.

Biosimilar developers face increasing pressure to accelerate timelines while maintaining product quality, process consistency, and cost efficiency. This application note showcases how the Gibco™ CHOvantage™ GS Cell Line Development Kit supports rapid generation of stable, high-producing biosimilar cell lines in as little as 14 weeks, with demonstrated scalability and reference-comparable product quality attributes.

Emerson describes the emerging industrial computing architecture as “Boundless Automation,” a transformative concept that redefines how digital systems operate within industrial environments. This architecture is built upon the seamless integration of three core computing domains: the intelligent field, the edge, and the cloud. Each domain plays a distinct yet interconnected role in processing and managing data.

The Advanced Therapies Congress USA is America's largest commercial cell and gene therapy conference and exhibition. The event is for the leaders of the world’s ATMP developers and their most senior executives in charge of the latest tech and strategies that are driving the industry forward. Join us in Boston for 2026!  Use code LSC20 for 20% off. Book your ticket now.

Get more Cell & Gene insight with our FREE newsletter Newsletter | July 15, 2026 NAMs are transforming toxicology with human-relevant, non-animal approaches. Learn what defines a NAM, how these methods work together, and why adoption is rapidly accelerating. Policy and scientific validation have aligned to shift drug development beyond animal models. New regulations and technologies are making human‑relevant methods the standard for preclinical research.